Seres Therapeutics, Inc. (MCRB)
NASDAQ · Healthcare
Seres Therapeutics, Inc. EBITDA 2015–2025
Seres Therapeutics, Inc. annual/quarterly ebitda history and growth rate from 2015 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Seres Therapeutics, Inc. ebitda for the quarter ending March 31, 2026 was -20.1 M, a 23.07% decrease year-over-year.
- Seres Therapeutics, Inc. ebitda for the twelve months ending March 31, 2026 was -95.5 M, a 82.99% increase year-over-year.
- Seres Therapeutics, Inc. annual ebitda for 2025 was -89.8 M, a 22.45% decrease from 2024.
- Seres Therapeutics, Inc. annual ebitda for 2024 was -115.8 M, a 38.66% decrease from 2023.
- Seres Therapeutics, Inc. annual ebitda for 2023 was -188.9 M, a 8.98% increase from 2022.
- Seres Therapeutics, Inc. annual ebitda for 2022 was -173.3 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Seres Therapeutics, Inc. EBITDA — FAQ
Seres Therapeutics, Inc. (MCRB) ebitda over the last 11 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see MCRB's ebitda history?
The chart and table above show Seres Therapeutics, Inc.'s ebitda by year and by quarter, including the growth rate.